Determining the Impact of Scaling up Mass Testing, Treatment and Tracking on Malaria Prevalence in Ghana

NCT04301531 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5861

Last updated 2023-05-06

No results posted yet for this study

Summary

Globally, malaria prevalence in 2016 was reported to have increased with 445,000 deaths, 91% of which occurred in sub-Sahara Africa with more than 75% being children. Individuals who carry the malaria parasite can either be symptomatic (showing signs and symptoms) or asymptomatic (without signs and symptoms). Asymptomatic malaria parasitaemia pose a very serious threat to malaria control efforts as they serve as reservoirs that fuel the transmission process. Therefore, interventions that target community-wide clearance of asymptomatic parasitaemia can drastically reduce malaria prevalence in the population and lead to elimination especially in endemic areas. Mass parasite clearance can deplete the parasite reservoirs and lower the transmission potential.

Efforts are ongoing to scale-up interventions that work such as use of Long Lasting Insecticidal Nets (LLIN), Intermittent Preventive Treatment in children (IPTc), and test, treat and track (TTT). However, there is need for mass testing, treatment and tracking (MTTT) of the whole population to reduce the parasite load before implementing the aforementioned interventions. Though, Seasonal Malaria Chemoprophylaxis (SMC) is adopted for selected localities in Ghana, the impact of such interventions could be enhanced, if combined with MTTT at baseline to reduce the parasite load. IPT of children in Ghana has demonstrated a parasite load reduction from 25% to 1%. However, unanswered questions include - could this be scaled up? What can be the coverage? What is needed for MTTT scale -up? In a pilot in Ghana, a coverage of more than 75% was achieved in target communities and reduced asymptomatic parasitaemia by 24% from July 2017 to July 2018. It is important to generate time series data to better analyse and understand the prevalence trends as well as the bottlenecks.

In designing interventions that aim at reducing the burden of malaria in children under five, for example, MTTT has largely been left out. This study explores the scale-up of interventions that work using community volunteers, hypothesising that implementing MTTT complemented by community-based management can reduce the prevalence of asymptomatic malaria parasite carriage in endemic communities. The effect of the interventions will be observed by comparing baseline data to evaluation data. This study will document the challenges and bottlenecks associated with scaling-up of MTTT to inform future efforts to scale-up the intervention.

Conditions

  • Malaria Asymptomatic Parasitaemia

Interventions

OTHER

Mass testing using RDTs

To determined the prevalence of asymptomatic malaria parasitaemia. In arm 1 all participants will be tested six times over the study period while in arm 2 the participants will be only be tested at baseline and evaluation.

DRUG

Treatment for all cases confirmed positive malaria cases with ACTs

During each mass testing, all confirmed positive cases are treated in both arms.

OTHER

Determination of Hb

Hb of all children in the subgroup study are measured using a haemocure photometer.

OTHER

Household survey

Determine the prevalence of febrile illnesses among children in the subgroup study

OTHER

Community-base management of malaria

Between interventions, participant who become febrile are tested and treated if confirmed positive for malaria by CHWs

Sponsors & Collaborators

  • Ghana National Malaria Control Programme

    collaborator UNKNOWN
  • Communities

    collaborator UNKNOWN
  • Noguchi Memorial Institute for Medical Research

    lead OTHER

Principal Investigators

  • Ndong Ignatius Cheng, PhD · Noguchi Memorial Institute for Medical Research

Study Design

Allocation
NON_RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
2 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-03-01
Primary Completion
2021-11-30
Completion
2023-01-31

Countries

  • Ghana

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04301531 on ClinicalTrials.gov